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Open source software may have been around for 17 years, but using an open source model to 
speed up drug discovery is a relatively new idea. This month, India is launching a new open source 
initiative for developing drugs to treat diseases such as tuberculosis, malaria, and HIV.Biophysicist Samir Brahmachari, Direc-
tor General of India’s Council of Sci-
entific and Industrial Research (CSIR), 
announced the launch this month of an 
open source drug discovery (OSDD) 
initiative to accelerate development of 
new drugs to treat infectious diseases 
that plague the developing world. “When 
it comes to health, India is in a state of 
war. There’s a war between health as 
a right and health as business,” says 
Brahmachari.
Just as the original open source soft-
ware was propelled by software develop-
ers motivated to contribute to large col-
laborative projects, proponents of OSDD 
believe that the global need for new 
low-cost drugs, particularly for treating 
neglected tropical diseases, will make this 
model effective. Because drug research is 
so complex, different OSDD initiatives are 
applying different strategies. For exam-
ple, CSIR aims to have a web-enabled 
interactive open source platform that 
will list the current design challenges for 
developing drugs to treat drug-resistant 
tuberculosis, malaria, and HIV. Research 
teams from CSIR labs across India and 
from other government institutions as well 
as individuals from universities and indus-
try can volunteer to contribute solutions 
to the posted drug design challenges. 
Contributions could include, for example, 
posting a new algorithm or information 
about a new drug target. As it will be open 
source, any scientist can contribute. Brah-
machari says that as an added incentive, 
software will be written enabling prob-
lem solvers and contributors to receive 
microcredits; once a certain number of 
microcredits has been accrued, the per-
son will receive a monetary reward. The 
first step in CSIR’s OSDD initiative is the 
launch of an open source website host-
ing information about Mycobacterium 
tuberculosis, the bacterial pathogen that causes tuberculosis. This informa-
tion includes gene sequences, expres-
sion, function, activity, and the response 
to drugs of all M. tuberculosis proteins 
as well as host-pathogen interactions 
(http:// mtbsysborg.igib.res.in).  Challenges 
for designing new drugs to combat tuber-
culosis will be posted shortly.
India’s federal government has com-
mitted $38 million for this initiative, 
and Brahmachari hopes to raise a third 
of the overall project cost from dona-
tions and charity. Sun Microsystems, a 
Californian technology company, has 
come on board as a long-term partner 
to “program manage” the IT part of the 
initiative, which like all modern drug dis-
covery efforts involves significant com-
putational infrastructure. “Sun will define 
the high level application and systems 
architecture for this initiative, and will 
provide help in identifying the appropri-
ate software integrator for the IT part of 
the project,” says Jaijit Bhattacharya, 
Director of public policy and corporate 
strategy at Sun Microsystems India. Sun 
will provide its open source software and 
will help in obtaining other software for 
the program, he says.
From Linux to Open Source Drug 
Discovery
OSDD is only a few years old but has 
its roots in the open source software 
movement started 17 years ago by Linus 
Torvalds, who developed the Linux 
operating system. Borrowing from the 
Linux concept, biologists started devel-
oping open source bioinformatics tools 
such as BioJava, BioSpice, BioRuby, 
BioPython, BioPerl, and others for data 
mining, visualization, simulation, sta-
tistics, data integration, and analysis. 
For example, Upinder S. Bhalla, asso-
ciate professor at the National Center 
for Biological Sciences (NCBS) in Ban-Cell galore, spearheads two open source 
NCBS programs: a simulator software 
called MOOSE (Multi-scale Object Ori-
ented Simulation Environment) and a 
database of signaling models called 
DOQCS (Database of Quantitative Cel-
lular Signaling). “We use the simulator 
ourselves, and we use our database 
for our research. That seems to keep 
the development on a practical track 
and motivates development of real-
world features,” he says. MOOSE has 
four active developers and gets about 
100 hits a day; DOQCS has one active 
developer and gets as many as 20,000 
noncommercial queries a month.
This sharing of bioinformatics know-
how has paved the way for more ambi-
tious projects such as CAMBIA, launched 
by molecular biologist Richard Jefferson 
in Australia as an international nonprofit 
institute for creating new technologies 
and tools to enable innovation in health, 
food security, and natural resource man-
agement for the developing world. CAM-
BIA has two spin-off projects: BiOS 
(Biological Innovation for Open Society; 
http://www.bios.net/daisy/bios/about/3.
html) and most recently Patent Lens (http://
www.patentlens.net/daisy/patentlens/
patentlens.html). A big success for BiOS 
has been its licensing of a gene transfer 
technology called TransBacter that can be 
used instead of the costly Agrobacterium 
for genetically engineering plants. More 
recently, CAMBIA launched Patent Lens, 
an open source freely accessible data-
base that searches the full-text of over 8 
million patents and applications world-
wide. “In biology we need new clarity in 
what’s out there [in terms of patented 
research], what’s coming down the turn-
pike, and the new legal and cultural instru-
ments to get past them,” says Jefferson. 
Patent Lens has a server that extracts 
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US patents and links them to GenBank 
and BLAST searches. CAMBIA and the 
University of Melbourne are discussing 
ways to use Patent Lens to jointly launch 
an international open innovation platform 
(IOI) to assist in searching patents filed 
worldwide, as currently there is no univer-
sal system for doing this.
OSDD is an offshoot of these ear-
lier ventures. One of the first OSDD 
initiatives, The Synaptic Leap (TSL) 
(http://www.thesynapticleap.org/), was 
launched by software engineer Ginger 
Taylor in November 2005. Her goal was 
to create an online research community 
that could connect and collaborate on 
research efforts for neglected tropical 
diseases such as the parasitic disease 
schistosomiasis. Currently, TSL has 
over 2000 unique site visits per month, 
most by active scientists from universi-
ties worldwide. Says chemist Matthew 
H. Todd at the University of Sydney, who 
leads the TSL’s biochemistry group, 
“there’s a huge pool of people out there 
wanting to do chemical synthesis and 
biological evaluation of compounds—
you just have to find them and coordi-
nate the effort efficiently.” Todd is work-
ing on improving the chemical synthesis 
of praziquantel, a drug currently used to 
treat schistosomiasis. “The drug needed 
to be made enantiopure rather than 
racemic. We have received a sugges-
tion for solving this problem and we are 
at least 75% of the way there,” he says. 
A related initiative is UsefulChem (http://
usefulchem.wikispaces.com/), set up 
by Drexel University chemist Jean-
Claude Bradley. Bradley has pioneered 
Open Notebook Science in which lab 
notebooks and raw research data are 
posted on the web for anyone to see 
and respond to (http://usefulchem.wiki-
spaces.com/All+Reactions). As for suc-
cess, Bradley says, “Probably the best 
example of a positive outcome from 
UsefulChem is finding two compounds 
that are somewhat active against 
malaria [in vitro],” blocking the activity 
of falcipain-2, a Plasmodium falciparum 
cysteine protease. “This demonstrates 
that a team of researchers can work 
together in the open—Rajarshi Guha 
from Indiana University did the docking 
calculations, my group at Drexel did the 
syntheses and Phil Rosenthal’s group at 
UCSF did the testing.”202 Cell 133, April 18, 2008 ©2008 Elsevier A Global Quest for Collaborative 
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Perhaps surprisingly, big pharma is 
becoming interested in OSDD. In 2000, 
the pharmaceutical giant Eli Lilly & Com-
pany in Indianapolis created a dedicated 
division, eLilly, to focus on using the 
Internet to improve the current drug R&D 
model. “Out of this came high profile 
ventures like InnoCentive and less visible 
ones such as Collaborative Drug Discov-
ery (CDD), Scienteur and Chorus,” says 
Bernard Munos, an advisor in corpo-
rate strategy to Lilly. In 2005, Lilly spun 
off InnoCentive and CDD as separate 
entities, retaining a small equity inter-
est. InnoCentive, cofounded by organic 
chemist Alph Bingham, is an “open inno-
vation marketplace” where users can 
select an R&D challenge posted by a 
company or a not-for-profit organization 
and attempt to solve it for a cash prize 
ranging from $5000 to $1 million (http://
www. innocentive.com/servlets/project/
ProjectInfo.po?s=AW). Bingham, who 
launched InnoCentive in 2001 with 21 
drug discovery challenges, says about 
the launch “For all the reduction-to-prac-
tice postings of new chemical materials, 
we had requested that the solver submit 
a sample of the targeted chemical struc-
tures…The receipt of these samples later 
that year and postmarked from all around 
the world, was marked evidence that the 
model was working.” Currently, InnoCen-
tive lists a number of successes on its 
website such as new methods to synthe-
size fluorinated ethers and butanoic acid 
and the identification of new drug targets 
for treating Duchenne Muscular Dystro-
phy. Among the posted challenges is 
one to find a diagnostic biomarker for the 
neurodegenerative disease amyotrophic 
lateral sclerosis (ALS), posted by an ALS 
patient group called Prize4Life. The chal-
lenge was answered by a dermatologist 
who proposed looking for biomarkers 
in skin instead of blood and urine. The 
problem solver received a $15,000 prize 
for his proposal and is working with the 
ALS Center at Columbia University to 
test the skin of about 50 ALS patients for 
suitable biomarkers.
Last year, Novartis Institutes for Bio-
medical Research in Cambridge, MA, 
together with the Broad Institute of Har-
vard and MIT and Sweden’s Lund Uni-
versity, collaborated to make all infor-Inc.mation about genes implicated in type 
2 diabetes obtained from genome-wide 
association studies freely available on 
the web in an effort to speed up elucida-
tion of the mechanisms underlying this 
complex disease (http://www.broad.mit.
edu/diabetes/). “This complexity is one 
of the reasons why we took the open 
approach to this collaboration. Clearly it 
will require many laboratories to clarify 
how and when these genes and loci may 
exert their influence on the development 
and/or progression of diabetes,” says 
Thomas E. Hughes, head of diabetes 
research at Novartis. “We are committed 
to having interactive and open collabora-
tions with innovative partners from aca-
demia and biotech,” he says. “It is not 
often that we have the injection of new 
information of this type in our field.” If the 
right opportunity presents itself in the 
future “we would consider using this col-
laboration model again,” says Hughes.
Taking industry involvement to a dif-
ferent level is the European Union’s new 
Innovative Medicines Initiative (IMI), a 
unique partnership between the Euro-
pean Community and the European 
Federation of Pharmaceutical Industries 
and Associations (EFPIA) (http://www.
imi-europe.org/). The goal of IMI is to 
help resolve key bottlenecks in European 
R&D with the goal of accelerating drug 
development in areas such as cancer, 
inflammation, and infectious diseases. 
With 2 billion Euros in funding from the 
EU 7th Framework Program and EFPIA 
members, and a call for proposals to 
be issued at the end of this month, all 
researchers working in Europe are eligi-
ble to apply. IMI adviser and intellectual 
property expert Bo Heiden of Sweden’s 
Chalmers University says, “IMI facilitates 
an open innovation platform for pre-drug 
development to facilitate the creation of 
safer drugs faster, not necessarily the 
open distribution of the drugs them-
selves developed through the help of the 
IMI platform.”
Negotiating the IP Maze
As the software open source model is 
translated into drug discovery efforts, 
issues of intellectual property (IP) and 
assigning credit need to be addressed. 
Says InnoCentive cofounder Bingham, 
“we are constantly learning and experi-
menting with new approaches for both 
the legal and the intellectual recognition 
of widespread contributions.” Mean-
while, Lilly’s Munos believes that IP pro-
tection is “an enabler of open-source 
drug R&D, not a threat.” The surest way 
to create a vibrant innovation network, 
he says, is to protect the IP it gener-
ates. “In each organization, there will be 
a debate, especially early on, between 
how much to disclose versus how much 
to protect,” he says. However, as orga-
nizations gain more experience in this 
field and as IP issues get streamlined, 
confidence and sharing will increase. 
“I do not expect free-riding to be a sig-
nificant problem because members will want to influence the direction of the 
network of researchers, and they will 
have to share in order to do so,” says 
Munos. As for India’s new OSDD initia-
tive, CSIR’s Brahamachari says, “I am 
not a socialist reformer and I am not anti 
intellectual property regime.” He pre-
dicts that CSIR’s new initiative will fol-
low a hybrid IP model by using a “click-
wrap” license that requires the users 
to agree that they will not file product 
patent applications in cases where they 
rely on open source data.
India’s OSDD initiative is still in its 
infancy and it is impossible to know how 
successful it will be. InnoCentive’s Bing-Celham truly applauds “the CSIR objective 
of mainstreaming this mode of research 
and its widespread applicability to drug 
development” but suggests that CSIR 
could use the InnoCentive platform. 
Matthew Todd thinks CSIR could adopt 
the existing TSL network to jumpstart 
the OSDD project. For his part, Braha-
machari is open to collaboration with 
these programs but still thinks India 
needs to go ahead with its own OSDD 
initiative. As Maharaj K. Bhan, head of 
the Indian Federal Department of Bio-
technology, points out, “It is good for the 
country. I don’t know if it will work, but 
champions don’t look for outcomes.”
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